Professor & Head, Department of Dermatology, St George Hospital, University of NSW, Sydney
We eagerly await the results of this pivotal clinical trial of dupilumab I designed together with dermatology colleagues Pascal Joly, Victoria Werth and Arsalan Shabbir for bullous pemphigoid. Here is the trial rationale and design. https://lnkd.in/gs5tZbcd
New Publication in Dermatology and Therapy: The analysis of an IL-13 inhibitor across EASI body regions and clinical signs of Atopic Dermatitis, results from ADvocate 1 & ADvocate 2 trials. View the full publication here: https://e.lilly/4ayAaKR
Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024
Lots of exciting developments in #psoriasis #psoriaticarthritis #lupus to follow. I guess that's why #venturecapital investing $250M+ here. #clinicaltrials #arthritis #medicine #heathcare
Today we presented positive data from a Phase 2 clinical trial of ESK-001, a highly selective allosteric TYK2 inhibitor, for the treatment of plaque #psoriasis at the American Academy of Dermatology Annual Meeting. Learn more: https://lnkd.in/e9pKPCBM #AAD2024
I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase
Latest living network meta-analysis (NMA) update published in JAMA Dermatology! We are delighted to share the results of our NMA, this time focused on lebrikizumab and how it compares to other systemic treatments for atopic dermatitis. Do check out our open access paper here: https://lnkd.in/gJEW39TY JAMA Dermatol. doi:10.1001/jamadermatol.2024.2192 Carsten Flohr and Aaron Drucker
Professor Dermatology Ghent University Hospital - Skin cancer specialist - (Skin) Cancer Research Institute Ghent ((Skin)CRIG) - president of EUROSKIN - Ambassador TEAM HOPE Stichting Tegen Kanker
Different clinicopathologically defined #nevus subtypes have different degrees of cytological atypia and different risk of association with #melanoma.
We are pleased that our retrospective study of atypical flat pigmented lesions, conducted by Veronique Clauwaert, has been accepted by the Journal of Investigative Dermatology. The publication was summarized as a poster at the Belgian Dermatology Days. Veronique won the 'Best Poster' award. 'Clinicopathologically defined nevus subtypes and associated melanoma risk' V. Clauwaert, E. Verhaeghe, Sofie De Schepper, Marc Haspeslagh, Lieve BROCHEZ
Experts in dermatology provide a comprehensive year in review regarding the management of plaque psoriasis, highlighting key therapeutic approvals from 2023. The discussion will highlight pivotal clinical studies supporting these approvals and our discussion will then pivot to have a special focus on addressing the unique challenges faced by treating patients with skin of color and treatment access barriers. Explore the series here: https://ow.ly/az7y50RSCnx
CEO @ Sibel Health | Ruth K. Freinkel MD Professor @ Northwestern University | Physician Engineer | Digital Health Leader | Board Certified Dermatologist | Head of the Medical Advisory Board - Geologie
Patient-reported outcomes tell part of the story— objective data fills the gaps. Asking patients how they feel will always be important. But, responses are too easily influenced to be fully reliable. Our sensors quantify nocturnal scratch with 93% sensitivity and 99% specificity against infrared camera labels in adults with atopic dermatitis published in the Journal of the American Academy of Dermatology. Pair this with patient voices, and better trial outcomes will quickly follow. PS - Read the full articile here: https://lnkd.in/gF_C6iSm
Lawrence Eichenfield, M.D., discusses studies from the 2024 American Academy of Dermatology Annual Meeting that have significant implications for the management of atopic dermatitis (AD). Watch this K-Cast episode to learn more about key insights on AD from #AAD2024 https://bit.ly/3V8OQvC #AtopicDermatitis #ManagedCare https://bit.ly/3V8OQvC
Account Development Representative RWE ppd Clinical Research Services Thermo Fisher Scientific
Want to learn more about our AtopicDermatitis registry. Let’s schedule a meeting and discuss how we can support your dermatology development initiatives. #rwe #rwd #registry #atopicdermatitis
Now available online American Academy of Dermatology #JAAD: our co-authored research paper. It describes the demographic, clinical, and treatment characteristics among CorEvitas #AtopicDermatitis (AD) Registry patients in the first 2.5 years after inception and stratified by current systemic therapy use. https://hubs.la/Q02rbhvB0 #RWE #RWD #diseaseregistry
Pharmacist , Reasercher , Clinical pharmacist , Clinical pharmacology , Dermatological Pharmacology
6moIL4 is the main for production of desmogline antibody in bullous skin autoimmunity So dupilumab is a selective iL4 and iL13 inhibitor as a novel treatment ,,,